Oxford Nanopore Hits £1.5bn Valuation With Latest £100m Round
Executive Summary
In one of the bigger private financing rounds seen this month so far, British genomics firm Oxford Nanopore Technologies has raised £100m ($140m) from a syndicate of APAC investors to expand its commercial activities. The latest funding round values the company at £1.5bn.
You may also be interested in...
Deal Watch, Licensing & Alliances: Amgen Places $66m Bet On Genetic Sequencing
Already partnered with Oxford Nanopore through its acquisition of deCODE Genetics, Amgen invests in the UK biotech to enhance its genomic capabilities. Aclaris licenses dermatology product Rhofade from Allergan. Other recent licensing and alliance deals...
Record Breaking First Half For Start-Ups Raising Cash In Europe
The first half of 2018 appeared promising for the European biopharma sector, with multiple large investment funds promising cash to young, innovative companies in the region – a turnaround after years of life science firms suffering from a funding drought across Europe.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.